Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002, for Owens & Minor, Inc. (O&M), a distributor of medical and surgical supplies. The filing includes unaudited consolidated financial statements and management's discussion and analysis. Notably, the company adopted SFAS 142 on January 1, 2002, ceasing the amortization of goodwill.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $966.7 million | $924.5 million |
| Gross Margin | $103.0 million (10.7%) | $98.9 million (10.7%) |
| Net Income | $10.8 million | $7.7 million |
| Diluted EPS | $0.29 | $0.22 |
| Operating Cash Flow | ($10.1 million) | $14.5 million |
| Long-Term Debt | $202.0 million | $203.4 million (Dec 2001) |
| Cash and Equivalents | $0.7 million | $0.9 million (Dec 2001) |
Liquidity: Combined outstanding debt and off-balance sheet receivables securitization totaled $242.0 million at March 31, 2002. The company maintained $211.3 million in unused credit under its revolving facility and the ability to sell an additional $185.0 million in receivables.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5% year-over-year, driven by a 6% per-day increase due to new business and deeper penetration of existing accounts.
- Profitability: Net income rose 40% to $10.8 million. Excluding goodwill amortization, adjusted net income increased 20% from the prior year.
- Expense Management: SG&A expenses improved to 7.8% of sales from 7.9%, aided by lower personnel and warehouse costs following customer transitions completed in 2001.
- Financing Costs: Net financing costs decreased to $3.4 million from $5.0 million, attributed to lower effective interest rates and refinancing activities.
- Cash Flow Volatility: Operating cash flow turned negative ($10.1 million used) compared to a positive $14.5 million in Q1 2001. This was primarily due to a $30.0 million net decrease in receivables sold under the securitization facility and a $30.5 million increase in accounts receivable.
Outlook, Risks, and Unusual Items
- Accounting Changes: The adoption of SFAS 142 eliminated goodwill amortization expense. The company performed a transitional impairment test and determined goodwill was not impaired as of January 1, 2002.
- Capital Structure Updates: Effective April 30, 2002, the company replaced its revolving credit facility (limit $150 million, expiring 2005) and receivables securitization facility (limit $225 million, expiring 2005). New agreements include covenants on net worth, leverage, and fixed charge coverage.
- Restructuring and Integration: The company continues to incur costs related to the 1999 Medix acquisition integration and a 1998 restructuring reserve, with charges of $127,000 and $265,000 respectively in Q1 2002.
- Risks: Key risks include cost-control pressures in the medical industry, dependence on large customers, supplier dependence, and potential goodwill impairment if business volume declines.
Investor Verification Checklist
- Verify the sustainability of the 5% sales growth given the competitive medical supply landscape.
- Confirm the impact of reduced receivables sales on future operating cash flow and working capital requirements.
- Monitor compliance with the new debt covenants (net worth, leverage, fixed charge coverage) established in the April 2002 credit agreements.
- Assess the adequacy of the $0.7 million cash balance against immediate liquidity needs, given the negative operating cash flow for the quarter.
- Review the status of pending legal proceedings referenced in the 2001 10-K for any material developments.